VIVA BIOTECH has completed the sale of a 2.33% equity stake in Viva Shanghai.
VIVA BIOTECH announced that the relevant matters regarding the sale of a 2.33% equity stake in Viva Shanghai have been completed, and the preconditions for the equity transfer have been met. After the completion, Raed Capital Holdings 2Ltd will hold a 2.33% equity stake in Viva Shanghai, reducing VIVA BIOTECH's equity interest in Viva Shanghai to 73.46%. Viva Shanghai remains a subsidiary of VIVA BIOTECH, and its financial performance will continue to be consolidated into the group's financial statements.
Zhitong App News, VIVA BIOTECH (01873) has announced the sale of 2.33% equity interest in Via Shanghai. All the preconditions for the equity transfer have been met, and the completion has been implemented on December 27, 2023. After the completion, Raed Capital Holdings 2Ltd will hold approximately 2.33% equity interest in Via Shanghai, while the Group's equity interest in Via Shanghai will decrease from approximately 75.79% to 73.46%. Via Shanghai will remain a subsidiary of the company, and its financial performance will continue to be consolidated into the Group's financial statements.
